Zoledronic Acidum CAS 118072-93-8 Puritas ≥99.7% API Factory Quality
Copia cum summa puritate et stabulo Quality
Chemical Name: Zoledronic Acidum
CAS: 118072-93-8
Potentissimus Farnesyl Diphosphate (FPP) Synthase Inhibitor
API High Quality, Commercial Production
| Nomen chemicum | Zoledronic acidum |
| Synonyma | ZOL 446, ZA, Zoledronate, CGP-4244, GP42446A, Zometa, Zomera;[1-hydroxy-2-(1H-imidazol-1-yl)-ethylidene] acidum bisphosphonicum |
| CAS Number | 118072-93-8 |
| CATTUS Number | RF-API90 |
| Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
| Formulae hypotheticae | C5H10N2O7P2 |
| M. Pondus | 272.09 |
| Liquescens punctum | 193.0~204.0℃ |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Aspectus | Alba ad Off-White Crystalline pulveris |
| Lepidium sativum | IR Imaginis specimen correspondet relationis vexillum |
| pH | 2.0~4.0 |
| Solubilitas | Parce Solubile in 0.1N Sodium Hydroxidis Solutio, in aqua et 0.1N acido hydrochlorico leviter solubili, in Ethanol fere Insolubili. |
| Substantiae cognatae | |
| Omnis immunditia | ≤0.10% |
| Totalis immunditias | ≤0.30% |
| Damnum in Siccatio | 5.0%~7.0% |
| Chloride | ≤0.04% |
| Phosphite | ≤0.50% |
| Phosphate | ≤0.50% |
| Metalla gravis | ≤10ppm |
| Puritas | ≥99.7% |
| Test Standard | Enterprise Standard |
| Consuetudinem | API, FPP Synthase Inhibitor, Hypercalcemia malignitatis (HCM) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
Acidum zoledronicum (CAS 118072-93-8) potentem bisphophonatum farnesyl diphosphatum (FPP) synthasis inhibitoris (IC50=20 nM).Osteoclastum mediatum ossis resorptionis nia.Item Ras nia significat et tumorem augmenti, et inducit apoptosin in cellulis carcinomatis pancreatici.Transitus epithelial-mesenchymalis adversatur et cancer pectoris cellulam renovationis per inactivationem NF-κB inhibet.Acidum Zoledronicum a FDA in MMI US probatum est propter hypercalcemiam malignitatis tractandam, complicationem metabolicam quae vitam minare potest.Hypercalcemia malignitatis fieri potest usque ad 50% aegrorum praecogniti cum cancro pectoris provecto, myeloma multiplex, et nonsullis cellulis pulmonis cancri.Haec conditio oritur, cum medietates chemicae per tumorem osteoclastarum causam productae sunt.Cum auctum est degradationis ossea, concomitans emissio calcii in plasma est.Cum sero collationes calcii celeriter elevant, renes onerarium tractare nequeunt, et hypercalcemia consequitur.Acidum zoledronicum efficaciter decrescit plasma calcii concentrationis per inhibitionem resorptionis ossis (inhibitionis osteoclasticae actionis et inductionis osteoclastis apoptosis).Acidum zoledronicum ab US FDA probatum est etiam ad curationem multiplex myeloma et metastases ossis cum carcinomate solido tumori substructi (exempli gratia prostrati et pulmonis).
